Indoco lines up new products for market push in Indian chronic/lifestyle sectors

The Indian generics firm, Indoco, has outlined a string of new initiatives to build its presence in the growing chronic and lifestyle disease segments, including a new division focused on cardiology and diabetes backed by a field force of more than 200 personnel and a string of proposed new launches.

The company told Scrip that the new division, Indoco CND (care in cardiology and diabetology), will begin with a revenue...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

06 Aug 2025

• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Quick Listen: Scrip’s Five Must-Know Things

04 Aug 2025

• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.

Metabolic Disease-Focused Poxel Teeters On The Edge

01 Aug 2025

• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Novo Selects Internal CEO To Recharge Growth

29 Jul 2025

• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

06 Aug 2025

• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.